Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High

PURPOSE: Microsatellite instability-high (MSI-H) colorectal carcinomas (CRCs) show high rates of response to immune checkpoint inhibitors (IOs). B2M mutations and protein loss have been proposed as causes of resistance to IOs, yet they are enriched in MSI-H CRC. We aimed to characterize B2M-mutant,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JCO Precis Oncol
Hauptverfasser: Middha, Sumit, Yaeger, Rona, Shia, Jinru, Stadler, Zsofia K., King, Sarah, Guercio, Shanna, Paroder, Victoriya, Bates, David D.B., Rana, Satshil, Diaz, Luis A., Saltz, Leonard, Segal, Neil, Ladanyi, Marc, Zehir, Ahmet, Hechtman, Jaclyn F.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2019
Schlagworte:
Original Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469719/
https://ncbi.nlm.nih.gov/pubmed/31008436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00321
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge